NCT04047290: A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

NCT04047290
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated symptomatic central nervous system (CNS) metastases; TO be eligible for the dose-expansion phase (Phase 1b), patient must not have prior exposure to any anti-PD-1, anti-PD-L1, anti-CTL4 antibody or any other antibody or drug targeting T-cell costimulation or checkpoint pathways such as ICOS, or agonists such as CD40, CD137, GITR, OX40 etc
https://ClinicalTrials.gov/show/NCT04047290

Comments are closed.

Up ↑